PEG-Verteporfin

PEG-Verteporfin, also known as poly(ethylene glycol)-conjugated Verteporfin, is a modified form of the photosensitizing agent Verteporfin, designed to enhance its pharmacokinetic properties for therapeutic applications. Verteporfin, chemically known as 9-(1-Methylethyl) ester 9H, 21H-benzo[2,10,13]porphyrin-9,21-dipropanoic acid, is a benzoporphyrin derivative originally developed as a photosensitizer for photodynamic therapy (PDT) in ophthalmology, particularly for treating age-related macular degeneration. Oncology: Investigated for PDT in cancers such as choroidal melanoma, prostate cancer, and glioblastoma, where PEGylation enhances delivery to hypoxic tumor regions. Ophthalmology: Used in variants of Visudyne® (the liposomal formulation of Verteporfin) for choroidal neovascularization.